Maintain TMO at benchmark weight; do not add at $628; pre-commit to $610/$605/$600 buy ladder on 10 EMA pullback with catalyst patience
HOLD with $612 trailing stop and tighter catalyst-adjacent trigger discipline; no additions at $628 where RSI 73.80 and zero margin of safety vs. $631.42 fair value create unfavorable risk-reward; pre-committed buy ladder at $610/$605/$600 on 10 EMA touch with volume confirmation after Jackson Hole (Aug 21–23) and Agilent (Aug 26) clear; trim 15–25% into $640+ without volume or if RSI >75; upgrade to Overweight on confirmed close above $643.99 on ≥3M shares; downgrade to Underweight on close below $585 with expanding volume; defensive collar appropriate given binary catalyst 48 hours away and stretched technicals.
| Position | Action |
|---|---|
| No new capital at $628; 50% of normal sizing on post-catalyst triggers | HOLD at benchmark weight |
| Trigger A: Close above $643.99 on ≥3M shares with RSI >65 | Scale-in Buy 50% at $645, add 50% on retest of $642 |
| Trigger A-1: Confirmed close above $620 with volume >2.5M and MACD histogram positive | Small starter position 15–20% of intended size |
| Trigger B: Pullback to $604–612 zone with ≥1.8–2M shares, RSI resetting to high 50s/low 60s, post-Agilent (8/26) and Jackson Hole (8/21–23) | Scale-in Buy: 1/3 at $610, 1/3 at $605, 1/3 at $600 |
| Push into $640+ resistance without volume confirmation, OR RSI >75 with MACD histogram deepening negative | Trim 15–25% + add defensive collar |
| Confirmed close above $643.99 on ≥3M shares | Upgrade to Overweight |
| Daily close below $585 with expanding volume | Downgrade to Underweight |
| Daily close below $531.60 (200 SMA zone) | Downgrade to Sell |
TMO is a compounder at an inflection point, not a melt-up running on fumes — the bears are anchoring to static fair value while fundamentals accelerate faster than models recalibrate, and the structural uptrend across all timeframes remains unbroken.
| Indicator | Value | Signal |
|---|---|---|
| close_200_sma | 533.73 | bullish |
| close_50_sma | 547.91 | bullish |
| close_10_ema | 612.44 | bullish |
| macd | 21.82 | bullish |
| macds | 20.35 | bullish |
| macdh | 1.48 | bullish |
| rsi | 73.80 | bearish |
| boll_middle | 595.59 | neutral |
| boll_ub | 637.00 | neutral |
| boll_lb | 554.18 | neutral |
| atr | 16.14 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Daily close above $643.99 on volume ≥3.0M with RSI holding above 65
Then: Scale-in Buy 50% at $645, add 50% on retest of $642 as support
Fair value revisions are running faster than models can recalibrate; TMO is in an earnings inflection year with 48% implied growth
↩ rebuts: “It's Fully Valued — DCF at Parity, PEG 2.05”
EV: +9.5% on multiple expansion alone to $687.75 at 25x forward EPS $27.51; upside path to 643.99 (52-week high) and beyond on earnings confirmation · concedes: Will not chase 637 at upper Bollinger band — position-sizing rule, not a sell signal; PEG ratio of 2.05 is high, but high because TMO is in an earnings inflection year; Risk/reward framework inverts if stock breaks 50 SMA at 548, 10 EMA at 612, and RSI rolls over — but all three breaking simultaneously is the bear's burden to prove
TMO is a compounder priced for the inflection already having happened, with no margin of safety at current valuations, technically stretched setup, and binary risk into Agilent 8/26 catalyst — making the risk-adjusted expected value negative at -0.7%.
EV: -0.7% · concedes: Structural uptrend is real — the question is whether it ends as slow grind or sharp reversion; Net debt/EBITDA of 3.3x number is accurate — the dispute is framing, not math; The moat is real — the dispute is whether it's worth 33.75x trailing earnings; Macro environment is genuinely supportive with 8% recession odds and soft-landing base case; Revenue growth at 10.5% is possible if life-sciences cycle stays hot
→ vs conservative: Using stale trailing P/E of 33.75x instead of forward P/E of 22.8x; the conservative is looking at the wrong valuation number
→ vs conservative: RSI at 73.80 and upper Bollinger tag are not sell signals in a structurally accelerating trend; pattern-matching to textbook ignores regime context
→ vs conservative: Waiting for $560-580 pullback is unrealistic base case; requires major macro shock or fundamental break in Q2 story that neither analyst expects
→ vs conservative: Net leverage concerns overblown; 3.3x debt/EBITDA with $6.24B FCF and 0.85 beta is investment-grade quality, not distressed credit
→ vs conservative: Goodwill/intangibles at 65% of assets and negative tangible book value must be balanced against $232B market cap those intangibles built
→ vs conservative: The analyst's -0.7% expected value is wrong because the 'upside' frame was defined as 1% gap to stale fair value instead of structural repricing
→ vs conservative: Anchor on 'we are at fair value' is exactly wrong frame for a best-in-class compounder with accelerating growth and 80% recurring revenue
→ vs neutral: HOLD triggers at $643.99 or $560-580 are fine for the first but unrealistic for second; missing the grinding upside to $680-720
→ vs neutral: Caution is being confused with discipline; opportunity cost of waiting outweighs downside protection
| vwma | 604.05 | bullish |
Support: 604.05 · 595.59 · 547.91 · 554.18 · 533.73 | Resistance: 637 · 634.7 · 628.15
TMO is in a powerful multi-timeframe uptrend with price (628.15) trading 17.7% above the 200-day SMA and 14.7% above the 50-day SMA, having accelerated after a July 23 gap-up that pushed the stock roughly +19.4% above pre-breakout levels. The MACD remains bullish with the histogram printing positive (1.48), and VWMA (604.05) is rising alongside price, confirming the advance on above-average volume. However, RSI at 73.80 signals overbought conditions and the 8/25 intraday high (637.01) nearly touched the upper Bollinger band (637.00), suggesting limited upside and potential mean-reversion risk. The recommended action is HOLD—existing holders should trail stops to the 10 EMA (612.44) while new longs should wait for pullbacks to the 604–612 zone rather than chasing at the upper band. A sustained close above 637 would unlock further upside, while a loss of VWMA (604) with RSI rollover would signal the first warning of a deeper correction toward the Bollinger middle (~596).
Market Capitalization
$232.26B
Current Price
~$625.95
52-Week Range
$435.27 – $643.99
50-Day MA
$544.74
200-Day MA
$534.12
Beta
0.847
Dividend Yield
0.30%
Revenue (TTM)
$46.336B
Gross Profit
$18.992B
EBITDA
$11.739B
Net Income
$6.967B
Free Cash Flow
$6.237B
EPS (TTM)
$18.61
Forward EPS
$27.51
ROE
13.52%
ROA
5.13%
Q2 2026 Revenue
$11.994B
Q2 2026 Gross Margin
40.7%
Q2 2026 Operating Margin
18.2%
Q2 2026 Net Income
$1.736B
Q2 2026 Diluted EPS
$4.68
Q1 2026 Revenue
$11.005B
Q4 2025 Revenue
$12.215B
Q3 2025 Revenue
$11.122B
Q2 2025 Revenue
$10.854B
Restructuring & M&A Charges (Q2 2026)
$98M
Cumulative Restructuring Charges (5 quarters)
~$400M
Diluted Shares Outstanding
371M
Share Count Reduction
~1.9%
Q2 2026 Operating Cash Flow
$2.125B
Q2 2026 CapEx
$0.450B
Q2 2026 Free Cash Flow
$1.675B
Q2 2026 Buybacks
$1.000B
Q2 2026 Dividends
$0.175B
Q1 2026 Buybacks
$3.000B
TTM Buybacks
>$5B
TTM Dividends Paid
~$662M
Q2 2026 D&A
$817M
FCF/Net Income Ratio
~0.90x
Total Assets
$113.174B
Goodwill + Intangibles
$73.438B
Net PPE
$10.755B
Total Receivables
$11.139B
Inventory
$5.627B
Cash & Equivalents
$4.064B
Total Debt
$42.549B
Long-Term Debt
$39.181B
Short-Term Debt
$3.368B
Net Debt
$38.485B
Net Debt (YoY)
$38.5B vs $30.7B
Total Stockholders' Equity
$52.680B
Total Liabilities
$60.366B
Working Capital
$8.296B
Current Ratio
1.551
Book Value/Share
$142.47
Debt/Equity Ratio
0.806
Net Debt/EBITDA
~3.3x
Tangible Book Value
negative $20.8B
Q1 2026 Business Acquisition
$8.872B
Q3 2025 Business Acquisition
$4.037B
Q1 2026 New Debt Issuance
$5.627B
Shares Outstanding (Q2 2026)
369.7M
P/E (TTM)
33.75
Forward P/E
22.83
PEG Ratio
2.05
P/B
4.41
EV/EBITDA (est.)
~23x
FCF Yield (TTM)
~2.7%
Goodwill on Balance Sheet
$54.8B
Recurring Consumables Revenue
~80%
Q2'26 Revenue YoY Growth
+10.5%
Q2'26 EPS YoY Growth
+9.3%
Strengths
Concerns
Thermo Fisher Scientific is a high-quality healthcare compounder with accelerating revenue growth of 10.5% YoY in Q2 2026, generating $46.3B in TTM revenue and $6.24B in free cash flow. The company trades at a premium but defensible valuation (forward P/E ~22.8x) supported by strong cash generation, defensive beta of 0.85, and aggressive capital return ($5B+ in buybacks), though elevated leverage (net debt $38.5B) and margin compression from restructuring/M&A charges warrant monitoring. The recent $8.87B acquisition in Q1 2026 and $4.04B acquisition in Q3 2025 demonstrate continued M&A strategy, with management funding these deals primarily through debt issuance. Final stance: HOLD (premium valuation offsets improving fundamentals; await better entry on pullback to $560–580).
Macro: Fed rate cuts: Polymarket prices 86% odds of NO Fed rate cuts in 2026 (up 1.2pp over the past week), implying a hawkish hold/higher-for-longer regime. US recession odds by year-end: 8% (rising slowly). Japan: 22% (falling sharply -8.5pp). UK: 11%. Soft-landing odds dominate, supportive of biopharma capex and academic research budgets. Inflation: <6% odds of CPI >5% in 2026; sub-4.5% inflation seen as ~88% probable. Consumer discretionary weakness consistent with mixed-soft-landing narrative, favoring defensive growth names like TMO.